Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function

• US 6,403,643 B1
• Filed: 07/26/2000
• Issued: 06/11/2002
• Est. Priority Date: 04/03/1997
• Status: Expired due to Fees

• Current Assignee: Laboratories Del Dr Esteve SA (Corporation Quimico Farmaceutica Esteve SA)
• Original Assignee: Laboratories Del Dr Esteve SA (Corporation Quimico Farmaceutica Esteve SA)
• Inventors: Esteve-Soler, Jose
• Primary Examiner(s): Criares, Theodore J.
• Application Number:
  US09/625,879
• Time in Patent Office: 685 Days
• Field of Search: 514/518, 514/517
• US Class Current: 514/518
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327

Abstract

A method for the use of 2,5-dihydroxybenzenesulfonic derivatives for normalizing endothelial function is disclosed. Preferred 2,5-dihydroxybenzenesulfonic derivatives are calcium dobesilate, ethamsylate and persilate.

Claims

1. A method for normalizing endothelial function comprising administering to a patient in need of such normalizing an effective amount of a 2,5-dihydroxybenzene sulfonic compound of general formula I:

in which

R represents H or SO₃⁻

;

B represents Ca⁺⁺ or H₂N©

₂H₅)₂;

n represents 1 or 2; and

m represents 1 or 2.

2. The method of claim 1 wherein the effective amount is between 0.5 and 2.0 g/day.

3. The method of claim 1 wherein said compound of general formula I is calcium 2,5-dihydroxybenzenesulfonate.

4. The method of claim 1 wherein said compound of general formula I is diethylamide 2,5-dihydroxybenzenesulfonate.

5. The method of claim 1 wherein said compound of general formula I is bis(diethylamide) 2,5-dihydroxybenzene-1,4-disulfonate.